Transaction summary
Mardi Dier, who serves as Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), sold a total of 1,962 shares of the companys common stock on March 6, 2026, generating approximately $854,000 in proceeds. The sales were executed in multiple trades with prices spanning from $425.08 to $437.65 per share.
Structure of the sales and trading plan
The disposition was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Dier adopted on September 2, 2025. Under that plan, 646 shares were sold at a single price of $431.94. The remaining 1,316 shares were sold across multiple transactions at prices ranging between $425.08 and $437.65 per share. The aggregate cash consideration from the March 6 sales is reported as approximately $854,000.
Concurrent awards and ownership position
Prior to the March 6 sales, Dier had activity recorded on March 4, 2026. On that date, Dier acquired 5,215 shares of common stock that are reported with a value of $0. In addition, Dier was granted stock options to purchase 6,519 shares of Madrigals common stock at an exercise price of $434.80 per share.
The option grant contains a vesting schedule that vests 25% of the shares on March 4, 2027, and thereafter vests an additional 6.25% every three months. Following the transactions recorded in early March, Dier directly owns 12,490 shares of Madrigal Pharmaceuticals common stock.
Recent financials and analyst reactions
These insider transactions come after Madrigals fourth-quarter 2025 financial report. The company reported earnings per share (EPS) of -$2.57, which missed the consensus forecast of -$0.60. Revenue for the quarter, however, exceeded expectations, coming in at $321.1 million versus the anticipated $310.82 million.
Following the quarter, Truist Securities reiterated a Buy rating on Madrigal and maintained a $640.00 price target, citing ongoing revenue growth tied to the commercial launch of Rezdiffra and describing the company as a market leader in an expanding and largely untapped market. H.C. Wainwright similarly reiterated a Buy rating with a $620.00 price target and noted that Rezdiffra has generated nearly $1 billion in net sales since its commercial launch. Together, those analyst updates reflect continued external confidence in Madrigals market position and revenue trajectory.
What the filings show
The filings and disclosures present a snapshot of insider activity, option compensation, and the companies most recent quarterly results. They document: the sale of 1,962 shares on March 6, 2026 under a Rule 10b5-1 plan; the March 4, 2026 award of 5,215 shares with a recorded value of $0; the grant of options to buy 6,519 shares at a $434.80 exercise price with a multi-step vesting schedule; and a resulting direct ownership of 12,490 shares by Dier.
Note: All transaction dates, share counts, prices, earnings, revenue figures, analyst ratings, and price targets are reported as disclosed in the company filings and analyst statements.